Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product ‘qER’. The US Food and Drug Administration’s decision covers four critical markers identified by Qure.ai’s emergency room product. Now the AI tool can be used to triage radiology scans with intracranial bleeds, mass effect, midline shift, and cranial fractures. Two of these capabilities – cranial fractures and midline shift – are exclusive to Qure.ai’s product. This means that the newly cleared qER suite will be able to triage nearly all critical markers visible on routine head CT scans.Every year, over 75 million CT scans are performed in the US, and more than 10,000 people die within 7 days of an emergency room discharge. There is, therefore, a clear need for a comprehensive and high-quality imaging AI tool to assist healthcare providers with prioritization and image interpretation.“Our target turnaround time for emergent studies is 30 minutes but leveraging AI for acutely critical conditions enables us to shorten that time. For conditions such as intracranial hemorrhage, time is of the essence and those precious minutes can be life-changing for our patients. We have done extensive validation of the Qure.ai qER solution and are excited to continue to partner with Qure.ai and improve care for our patients” says Benjamin W. Strong, MD, Chief Medical Officer of vRad, the leading teleradiology services provider in the United States.